<DOC>
	<DOCNO>NCT00859001</DOCNO>
	<brief_summary>Study phase : Phase II Investigational product , dosage , route administration : Ibritumomab tiuxetan ( Zevalin ) compose murine IgG1 monoclonal antibody ( ibritumomab ) covalently bound chelate agent tiuxetan . To prepare active therapeutic agent [ 90Y ] -ibritumomab tiuxetan , antibody chelate Î²-emitter yttrium-90 chloride immediately intravenous administration . Treatment [ 90Y ] -ibritumomab tiuxetan precede infusion rituximab ( Rituxan , Mabthera ) order optimize biodistribution radiolabeled antibody deplete CD20 positive B-cells . Rituximab chimeric human/murine IgG1 monoclonal antibody . The Zevalin study regimen give infusion rituximab 250 mg/m2 ( biodistribution image dosimetry compulsory ) 185 MBq ( 5mCi ) [ 111In ] -ibritumomab tiuxetan Day 1 follow 7 9 day later single dose 14.8 MBq/kg ( 0.4 mCi/kg ) [ 90Y ] -ibritumomab tiuxetan , maximal dose 1184 MBq ( 32 mCi ) , precede 250 mg/m2 rituximab . Indication : stage II-IV follicular lymphoma ( FL ) grade I-II 4 cycle FMR Study objective : Evaluation efficacy safety [ 90Y ] -ibritumomab tiuxetan , well assessment quality life Patient population : Patients 4 cycle treatment FMR Study design : Prospective , multicenter , open-label study design treat patient sequential front-line treatment represent 4 cycle FMR plus Zevalin Duration treatment : Four month FMR two treatment day one week apart follow 12-week safety period Zevalin Duration study : Estimated duration study 18 month Primary efficacy parameter : Overall response rate complete response rate Secondary efficacy parameter : Overall survival , Disease-free survival , health-related quality life . Safety parameter : Vital sign , adverse event ( AEs ) , hematology , blood chemistry , immunoglobulin level Number study center : 4 study center Italy T otal number patient , statistical rationale provide : Expected total 55 patient . The final sample size base number event observe primary efficacy endpoint calculate sequential statistical model . Adverse event : AEs observe , mention upon open question and/or spontaneously report document . Planned start end recruitment : Start recruitment : 3rd quarter 2006 . End recruitment : 1st quarter 2007</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Subsequent Treatment With Zevalin ( Ibritumomab Tiuxetan ) Study Patients With Follicular Grade I-II Lymphoma After 4 Cycles Fludarabine-Mitoxantrone-Rituximab ( FMR ) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm FL grade III accord REAL/WHO classification ( initial diagnosis make prior start FMR therapy ) ; FLIPI 3 Central pathology review confirm FL grade III diagnosis CD20 positivity , evidence/evidence infiltration &lt; 25 % FL bone marrow ; The first part treatment FL must 4 cycle standard FM chemotherapy ( fludarabine 25 mg/m2/day day 1 3 mitoxantrone 10 mg/m2 day 1 ) combination rituximab ( 375 mg/m2 ) ; Complete remission ( CR ) , unconfirmed complete remission ( CRu ) , partial response , nonresponder accord International Workshop Response Criteria NHL describe Cheson et al four cycle FMR . CT scan neck , thorax , abdomen , pelvis PET total body must perform within 3 week last dose last course FMR ; Patients 18yearsofage old time accrual ; WHO performance status ( PS ) 0 2 within 1 week accrual ; Absolute neutrophil count ( ANC ) 1.5 x 109/L within 1 week accrual ; Hemoglobin ( Hgb ) than10 g/dL within 1 week accrual ; Platelets 150 x 109/L within 1 week accrual . Written inform consent obtain accord local guideline Presence malignancy history prior malignancy except nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma ; Prior radioimmunotherapy , radiation therapy , NHL therapy ; Presence gastric , central nervous system ( CNS ) , testicular lymphoma first diagnosis ; Histological transformation lowgrade NHL ; Known seropositivity hepatitis C virus ( HCV ) hepatitis B surface antigen ( HbsAg ) ; Known history HIV infection ; Abnormal liver function : total bilirubin &gt; 1.5 x ULN ALT &gt; 2.5 x ULN within 1 week accrual ; Abnormal renal function : serum creatinine &gt; 2.0 x ULN within 1 week accrual ; Known hypersensitivity murine chimeric antibody proteins ; GCSF GMCSF therapy within two week ( four week pegylated ) prior screen laboratory sampling ; Concurrent severe and/or uncontrolled medical disease ( e.g. , uncontrolled diabetes , congestive heart failure , myocardial infarction within 6 month study , unstable uncontrolled hypertension , chronic renal disease , active uncontrolled infection ) could compromise participation study ; Male female patient childbearing potential unwilling practice effective contraception study unwilling unable continue contraception 12 month last dose study treatment ; Female patient pregnant currently breastfeed ; Treatment investigational drug le 4 week plan Day 1 nonrecovery toxic effect therapy ; Surgery le 4 week plan Day 1 nonrecovery side effect surgery ; Concurrent corticosteroid use reason except premedication case know suspected allergy contrast medium premedication potential side effect rituximab treatment ; Unwillingness inability comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>